VAI-SU2C Epigenetics Dream Team
9 results.
MEMPHIS, Tenn. (Oct. 10, 2024) — Immunotherapy, using a patient’s own immune system to treat disease, has shown promise in some patients with cancer but…
GRAND RAPIDS, Mich. (March 27, 2024) — A pair of medications that make malignant cells act as if they have a virus could hold new promise for…
Since October 2014, the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team has supported and launched breakthrough clinical trials that explore potential new…
GRAND RAPIDS, Mich. (Nov. 1, 2022) — A pair of cancer medications that act as a one-two punch against malignant cells demonstrated increased survival in…
GRAND RAPIDS, Mich. (April 4, 2019) — A new study out today in Cancer Cell shows that blocking specific regions of a protein called…
GRAND RAPIDS, Mich. (Oct. 12, 2017)—Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team (VARI-SU2C) scientists have been awarded two…
Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial
GRAND RAPIDS, Mich. (March 7,…
EDITOR’S NOTE: Maintaining proper nutrition is an important part of cancer therapy. Patients are urged to consult their doctors before making any change to their…